Healthcare -
Biotechnology - NASDAQ - US
$ 2.27
0 %
$ 229 M
Market Cap
-0.84
P/E
1. INTRINSIC VALUE
Balance Sheet
Acelyrin, Inc.
| Current Assets | 481 M |
| Cash & Short-Term Investments | 448 M |
| Receivables | 30.2 M |
| Other Current Assets | 2.88 M |
| Non-Current Assets | 10.2 M |
| Long-Term Investments | 0 |
| PP&E | 8.39 M |
| Other Non-Current Assets | 1.77 M |
| Current Liabilities | 26.6 M |
| Accounts Payable | 4.89 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 21.7 M |
| Non-Current Liabilities | 6.27 M |
| Long-Term Debt | 6.27 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Acelyrin, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 316 M |
| Operating Income | -316 M |
| Other Expenses | -68 M |
| Net Income | -248 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Acelyrin, Inc.
| Net Income | -248 M |
| Depreciation & Amortization | -18 M |
| Capital Expenditures | -1.25 M |
| Stock-Based Compensation | 45 M |
| Change in Working Capital | -77.4 M |
| Others | -64 M |
| Free Cash Flow | -305 M |
Wall Street Analysts Price Targets
Acelyrin, Inc.
Wall Street analysts predict an average 1-year price target for SLRN of $11 , with forecasts ranging from
a
low of
$6 to a high of $15 .
SLRN Lowest Price Target
Wall Street Target
6 USD
164.32%
SLRN Average Price Target
Wall Street Target
11 USD
384.58%
SLRN Highest Price Target
Wall Street Target
15 USD
560.79%
4. DIVIDEND
ANALYSIS
SLRN does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Acelyrin, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
68.9 K USD 3
6-9 MONTHS
0 USD 0
9-12 MONTHS
6.86 USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company's special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company's merger agreement with Alumis Inc. (Nasdaq: ALMS). As previously announced, under the terms of the amended merger agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned at the closing of the transaction.
globenewswire.com
- 1 month ago
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today
globenewswire.com
- 1 month ago
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockholders to vote today FOR the proposed merger LOS ANGELES, May 01, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reiterated its confidence that the proposed combination with Alumis Inc. (Nasdaq: ALMS) is the best path forward and the most value-maximizing outcome for all ACELYRIN stockholders. Bruce Cozadd, Chair of the ACELYRIN Board of Directors and member of the independent transaction committee (the “Transaction Committee”), said, “The ACELYRIN Board and management team are confident that the proposed merger with Alumis represents the most value-maximizing path forward for our company's stockholders.
globenewswire.com
- 1 month ago
Alumis and ACELYRIN Announce Amended Merger Agreement
ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis
globenewswire.com
- 1 month ago
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acelyrin, Inc. (NasdaqGS: SLRN) to Alumis Inc. (NasdaqGS: ALMS). Under the terms of the proposed transaction, shareholders of Acelyrin will receive 0.4274 shares of Alumis common stock for each share of Acelyrin that they own. KSF is seeking to determine whether this consideration and the process that led to i.
businesswire.com
- 2 months ago
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners' continued rapid accumulation of 8.8% of ACELYRIN'S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan (“Rights Plan”).
globenewswire.com
- 3 months ago
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC.
globenewswire.com
- 3 months ago
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, after due consideration in consultation with its independent financial and legal advisors, its Board of Directors determined that the unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, is not reasonably expected to result in a superior proposal to the planned merger with Alumis Inc. (Nasdaq: ALMS).
globenewswire.com
- 3 months ago
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, to acquire all of the outstanding shares of ACELYRIN for $3.00 per share in cash, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of ACELYRIN's development programs or intellectual property.
globenewswire.com
- 3 months ago
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acelyrin, Inc. (NasdaqGS: SLRN) to Alumis Inc. (NasdaqGS: ALMS). Under the terms of the proposed transaction, shareholders of Acelyrin will receive 0.4274 shares of Alumis common stock for each share of Acelyrin that they own. KSF is seeking to determine whether this consideration and the process that led to i.
businesswire.com
- 4 months ago
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.
NEW YORK , Feb. 7, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by ACELYRIN, INC. (NASDAQ: SLRN) and its board of directors concerning the proposed acquisition of the company by Alumis Inc. (NASDAQ: ALMS).
prnewswire.com
- 4 months ago
SLRN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ACELYRIN, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ACELYRIN, INC. (NASDAQ: SLRN) to Alumis Inc. for 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock is fair to ACELYRIN shareholders. Halper Sadeh encourages ACELYRIN shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The.
businesswire.com
- 4 months ago
8. Profile
Summary
Acelyrin, Inc. SLRN
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 229 M
Dividend Yield
0.00%
Description
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Contact
4149 Liberty Canyon Road, Agoura Hills, CA, 91301
https://www.acelyrin.com
IPO
Date
May 4, 2023
Employees
83
Officers
Ms. Patricia A. Turney
Chief Technical Operations Officer
Dr. Shephard Mpofu M.D.
Chief Medical Officer
Mr. K. Amar Murugan J.D.
Chief Legal Officer
Mr. Kenneth A. Lock
Chief Commercial Officer
Ms. Mina Kim J.D.
Chief Executive Officer & Director
Mr. Tyler Marciniak
Vice President of Investor Relations, Communications & Corporate Operations
Ms. Kelly Chow
Chief People Officer